Skip to main content
. 2021 Nov 18;601(7893):410–414. doi: 10.1038/s41586-021-04231-6

Fig. 1. Vaccine design and study schema.

Fig. 1

a, Designs of the CVnCoV and CV2CoV mRNA vaccine candidates. Both vaccines are based on CureVac’s RNActive platform and encode SARS-CoV-2 spike protein with di-proline mutations. The vaccines differ in their unique non-coding regions, as shown. b, Non-human primate vaccine study schema. Cynomolgus macaques were immunized intramuscularly (i.m.) on day (D) 0 with CVnCoV (n = 6) or CV2CoV (n = 6) mRNA vaccine or were designated as sham (n = 6). The animals were boosted at week 4 and were challenged at week (W) 8. Samples were collected weekly after immunization and on days 0, 1, 2, 4, 7 and 10 after challenge for immunological and virological assays. PP, K986P and V987P mutations; HSL, histone stem–loop.